Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Substance Use Disorders Affecting Sleep

Substance Use Disorders Affecting Sleep

Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploring study dropout in drug trials for adults with PTSD: insights from a conventional and individual participant data meta-analysis.

European journal of psychotraumatology·2025

Same author

Brain derived neurotrophic factor and treatment outcomes among veterans attending an intensive treatment program for posttraumatic stress disorder.

Journal of psychiatric research·2024

Same author

What good are positive emotions for treatment? A replication test of whether trait positive emotionality predicts response to exposure therapy for social anxiety disorder.

Behaviour research and therapy·2023

Same author

Using pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT.

Journal of psychiatric research·2023

Same author

Protocol for a multi-site randomized controlled trial of a stepped-care intervention for emergency department patients with panic-related anxiety.

BMC psychiatry·2022

Same author

Abnormal intestinal milieu in posttraumatic stress disorder is not impacted by treatment that improves symptoms.

American journal of physiology. Gastrointestinal and liver physiology·2022

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Redefining affective disorders: relevance for drug development.

Steven D Targum¹, Mark H Pollack, Maurizio Fava

¹Department of Psychiatry, Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. sdtargum@yahoo.com

CNS Neuroscience & Therapeutics

|May 17, 2008

Summary

Rigid diagnostic systems hinder drug development. This study proposes symptom-specific patient selection criteria for more effective central nervous system (CNS) clinical trials.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

An Olfactory Preference Test for Measuring Olfactory Hedonic Biases in Mouse Models of Depression

An Olfactory Preference Test for Measuring Olfactory Hedonic Biases in Mouse Models of Depression

Published on: July 11, 2025

Related Experiment Videos

Last Updated: Jul 5, 2026

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

An Olfactory Preference Test for Measuring Olfactory Hedonic Biases in Mouse Models of Depression

An Olfactory Preference Test for Measuring Olfactory Hedonic Biases in Mouse Models of Depression

Published on: July 11, 2025

Area of Science:

Neuroscience
Clinical Pharmacology
Psychiatry

Background:

Current diagnostic systems (e.g., DSM-IV) may not adequately capture patient heterogeneity in central nervous system (CNS) clinical trials.
Patient selection based on broad diagnoses can lead to enrollment of individuals not representative of the target illness, potentially compromising drug efficacy evaluation.
Existing classification systems may not align with the specific mechanisms of action of novel drug entities.

Purpose of the Study:

To propose operational criteria for a more symptom-specific and ecologically valid approach to patient identification in clinical trials.
To address limitations in current diagnostic and patient selection processes that impede the evaluation of new drug entities.
To enhance the precision of patient selection in CNS drug development by focusing on primary nosological entities.

Main Methods:

Review and critique of current diagnostic classification systems and patient selection methodologies in CNS clinical trials.
Development of proposed operational criteria for identifying patients based on symptom-specific and outcome-oriented approaches.
Emphasis on aligning patient characteristics with the intended mode of action of novel therapeutic agents.

Main Results:

Identification of limitations in rigid diagnostic systems for evaluating drugs with specific mechanisms of action.
Proposal of a framework for selecting patients based on the primary nosological entity and acute symptoms targeted by a drug.
Advocacy for a more symptom-specific and ecologically valid approach to patient identification.

Conclusions:

A shift towards symptom-specific patient selection is crucial for effective clinical drug development in CNS disorders.
Operationalizing criteria for identifying the 'valid patient' based on targeted symptoms will improve trial outcomes.
This approach aims to enhance the reliability and validity of clinical trial results for novel CNS therapies.